Targeted therapy for hepatocellular carcinoma using nanotechnology

28 Aug 2014

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-associated death worldwide.

These regrettably poor prognoses are due to the difficulty in treating this cancer using conventional chemotherapeutic drugs such as doxorubicin, epirubicin, cisplatin, 5-fluorouracil, etoposide or combinations therein.

This may be attributed to the fact that conventional medicines are not able to reach a sufficient concentration in the liver tumour cells without reaching levels that are harmful to the rest of the body.

Considering the large percentage of patients who are deemed ineligible to undergo conventional curative interventions, it is highly important to develop alternative drug treatment options that are able to target the tumour tissues, without inducing toxicity in other parts of the body.

Now a team of scientists, led by Prof Taeghwan Hyeon at the Institute for Basic Science (IBS)/Seoul National University and Prof Kam Man Hui at the National Cancer Center Singapore, has screened a library containing hundreds of natural products against a panel of HCC cells to find a better drug candidate.

The screen uncovered a compound named triptolide, a traditional Chinese medicine isolated from the thunder god vine (Tripterygium wilfordii (Latin) or lei gong teng (Chinese)) which was found to be far more potent than current therapies.

Studies from other researchers corroborate our findings as triptolide has also found to be very effective against several other malignant cancers including; pancreatic, neuroblastoma and cholangiocarcinoma.

However, this excitement was tempered when the drug was administered to mice as the increased potency was coupled with increased toxicity as well.

Maximising potency, mitigating toxicity

Prof Hyeon et al. endeavoured to alleviate the toxic burden by increasing the specific delivery of the drug to the tumour using a nanoformulation.

The designed formulation was a pH-sensitive nanogel coated with the nucleotide precursor, folate.

The researchers began by esterfying the polymer pluronic F127 with folate to make the coating material.

They then polymerised β-benzyl-L-aspartate N-carboxy anhydride to make the core material pH-sensitive due to repulsive forces upon protonation under acidic conditions.

"The combination of the two polymers forms a core/shell structured nanoparticle in water," explains Prof Hyeon.

"We loaded triptolide into the hydrophobic core to produce a kind of drug-nanogel."

A tumour model of folate-overexpressing HCC was then used to examine the effect of the nanogel formulation versus the free drug.

As expected, the nanogel triptolide showed increased tumour accumulation and uptake into the tumour cells where the decreasing pH efficiently triggered release of the entrapped triptolide.

The result was as hypothesised: In experiments on mice with HCC, the team found that its coated triptolide accumulated in the inflamed tumour tissues.

Once there, the folate-targeted ligand enhances the HCC cells to take up the anticancer drug.

Since the fluid inside tumour cells is more acidic (with a pH of around 6.8) compared to normal tissue (which has a pH of about 7.4), the drop in pH causes the coating to fall apart, and release the pure form of the triptolide, which then destroys the tumour cells, showing greater efficacy against the tumour and decreasing the overall toxicity.

The mechanism of action of Nf-Trip-FR represents an auspicious therapeutic approach

While these initial proof-of-concept studies have been promising, many drugs fail to become an IND (Investigational New Drug); fewer still effectively replicate their results in human trials.

However, a felicitous discovery occurred while the researchers were examining the mechanism of triptolide's activity.

Researchers at the National Cancer Center Singapore ran a profile on the effects triptolide had on protein expression in a variety of HCC cells.

From this they learned triptolide primarily reduced the levels of two proteins, AURKA and CKS2, although the mechanism is still not known.

The researchers then cross-checked these proteins against a clinical database of HCC patients and found an increased expression of these proteins correlates with the aggressiveness of the cancer.

Thus, it is hoped the negative effect triptolide has on these proteins could prove beneficial in terms of clinical outcomes when this drug finally becomes accepted for clinical studies in cancer patients.

The work is detailed in ACS Nano.

Source: Institute for Basic Science